The company is up by 13.36% since yesterday’s close of 1.84 making it one of today’s top gainers. More than 3,013,948 shares have changed hands.
Company shares last traded at $2.09 which is impressively higher than $1.87, the 50 day moving average and significantly higher than the 200 day moving average of $1.87. The 50 day moving average moved up $0.22 and the 200 day average was up $0.22.
Traders are feeling more bearish on shares of the company as shown by the rise in short interest. The stock experienced a rise in short interest of 1.90% between August 15, 2017 and August 31, 2017. Short shares grew 32,448 over that period. The days to cover decreased to 6.0 and the percentage of shorted shares was 0.18% on August 31.
Here are a few substantial investment firms who have updated their positions. As of the end of the quarter Ubs Group Ag had disposed of a total of 18,718 shares trimming its holdings by 94.7%. The value in dollars decreased from $137,000 to $3,000 decreasing 97.8% since the last quarter. As of quarter end Novo A/s had sold 49,786 shares trimming its position 3.9%. The value of the company’s investment in HTG Molecular Diagnostics, Inc. went from $8,859,000 to $3,273,000 a change of 63.1% quarter over quarter.
As of the end of the quarter Blackrock Inc. had sold 1,543 shares trimming its stake by 71.9%. The value of the investment in HTG Molecular Diagnostics, Inc. decreased from $15,000 to $2,000 a change of $13,000 for the reporting period. Putnam Investments LLC cut its position by shedding 513,099 shares a decrease of 100.0% from 03/31/2017 to 06/30/2017. Putnam Investments LLC claims 0 shares valued at $0. The value of the position overall is down by 100.0%.
In the latest earnings report the EPS was $-2.95 and is projected to be $-2.42 for the current year with 11,448,000 shares presently outstanding. Next quarter’s EPS is forecasted at $-0.48 and the next full year EPS is anticipated to be $-1.72.
HTG Molecular Diagnostics, Inc., launched on December 14, 2000, is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Business’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Business’s HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Business’s HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument..